Alps Advisors Inc. Increases Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Alps Advisors Inc. grew its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 43.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,137 shares of the medical device company's stock after acquiring an additional 5,219 shares during the period. Alps Advisors Inc.'s holdings in DexCom were worth $1,170,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Proficio Capital Partners LLC purchased a new stake in shares of DexCom in the 4th quarter valued at $5,812,000. Golden State Wealth Management LLC boosted its holdings in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of DexCom by 29.3% in the 1st quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock valued at $209,000 after acquiring an additional 702 shares during the last quarter. Private Trust Co. NA boosted its holdings in shares of DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after acquiring an additional 335 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC boosted its holdings in shares of DexCom by 34.2% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock valued at $357,000 after acquiring an additional 1,333 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In related news, Director Nicholas Augustinos sold 3,672 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the sale, the director directly owned 33,411 shares in the company, valued at approximately $2,766,430.80. This trade represents a 9.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the sale, the director owned 56,621 shares of the company's stock, valued at approximately $4,706,903.73. The trade was a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,190 shares of company stock valued at $2,281,732 over the last ninety days. 0.32% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

DXCM has been the topic of several recent research reports. Cfra Research raised shares of DexCom to a "hold" rating in a report on Friday, March 21st. Morgan Stanley boosted their target price on shares of DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research note on Tuesday. The Goldman Sachs Group started coverage on shares of DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 target price for the company. Wall Street Zen cut shares of DexCom from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Finally, Robert W. Baird decreased their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $99.60.

DexCom Price Performance

Shares of NASDAQ DXCM traded down $0.03 during mid-day trading on Thursday, reaching $84.10. The company's stock had a trading volume of 4,777,194 shares, compared to its average volume of 4,434,549. The stock has a 50-day moving average of $84.51 and a two-hundred day moving average of $80.13. The stock has a market capitalization of $32.98 billion, a P/E ratio of 62.76, a P/E/G ratio of 1.79 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $116.35.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 12.90% and a return on equity of 30.05%. DexCom's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the company earned $0.32 earnings per share. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.